Financial Performance - For the nine months ended December 31, 2020, the group recorded total revenue of approximately HKD 36,554,000, a decrease of about 73.12% compared to HKD 135,970,000 for the same period in 2019[4] - For the nine months ended December 31, 2020, the loss attributable to owners of the company was approximately HKD 15,880,000, compared to a loss of HKD 6,556,000 in 2019[4] - For the three months ended December 31, 2020, the loss attributable to owners of the company was approximately HKD 6,879,000, compared to a loss of HKD 5,651,000 in 2019[4] - The gross profit for the nine months ended December 31, 2020, was HKD 4,799,000, compared to HKD 4,367,000 in 2019[6] - The operating loss for the nine months ended December 31, 2020, was HKD 24,668,000, compared to HKD 4,484,000 in 2019[6] - The total comprehensive loss for the nine months ended December 31, 2020, was HKD 22,750,000, compared to HKD 6,909,000 in 2019[8] - The basic loss per share attributable to owners of the company for the nine months ended December 31, 2020, was HKD 0.563, compared to HKD 0.225 in 2019[10] - For the three months ended December 31, 2020, the company reported a revenue of HKD 14,017,000, a decrease from HKD 35,187,000 in the same period of 2019, representing a decline of approximately 60%[23] - The basic loss per share for the three months ended December 31, 2020, was HKD 6,879,000, compared to HKD 5,651,000 for the same period in 2019[26] - The basic loss per share for the nine months ended December 31, 2020, was HKD 15,880,000, an increase from HKD 6,556,000 in the same period of 2019[26] Dividends and Share Capital - The board of directors does not recommend the payment of dividends for the nine months ended December 31, 2020[4] - The company did not recommend any dividend for the nine months ended December 31, 2020, consistent with the previous year[25] - The total issued share capital of the company as of December 31, 2020, was approximately HKD 29,168,000, comprising 2,818,249,944 ordinary shares and 98,500,000 non-voting convertible preference shares[16] Administrative and Operational Expenses - The company reported a significant increase in administrative expenses, totaling HKD 47,186,000 for the nine months ended December 31, 2020, compared to HKD 54,963,000 in 2019[6] - Sales and distribution expenses were approximately HKD 11,225,000, down 84.22% from HKD 71,113,000 year-on-year, primarily due to the sale of Jiaxing Hospital[32] - Administrative expenses decreased by approximately 14.15% to HKD 47,186,000 from HKD 54,963,000 in the previous year, also attributed to the sale of Jiaxing Hospital[32] Corporate Governance and Compliance - The company’s financial statements are prepared in accordance with Hong Kong Financial Reporting Standards[20] - The audit committee reviewed the unaudited condensed consolidated results, which were prepared in accordance with applicable accounting standards and GEM listing rules[76] - The company has complied with the corporate governance code as set out in the GEM listing rules during the nine months ended December 31, 2020[70] - The remuneration committee is responsible for determining the specific remuneration packages of all executive directors, including benefits and compensation[73] - The nomination and corporate governance committee was established to review the board's structure and recommend suitable candidates for board membership[74] - The company has adopted a code of conduct regarding securities trading by directors, which has been adhered to during the review period[69] Shareholder Information - As of December 31, 2020, the company’s major shareholder, Xingyang Global Limited, holds 1,680,459,460 shares, representing approximately 59.63% of the total issued shares[58] - Zheng Huixian, a spouse of a director, holds 1,739,459,460 shares, accounting for approximately 61.72% of the total issued shares[58] - New Hope International (Hong Kong) Limited owns 343,217,539 shares, which is about 12.18% of the total issued shares[58] Future Plans and Developments - The company plans to expand its services through integrated and specialized medical models, anticipating more opportunities in the healthcare sector as indicated by the national economic and social goals[35] - The company aims to introduce new treatment models for diabetes and other chronic diseases while enhancing service quality and adopting new medical technologies[36] - The Putian Edinburgh Friendly Hospital has commenced trial operations, and the group is currently evaluating its operational status to formulate future plans[46] - The company is collaborating to establish an International Diabetes Center in Hainan, aiming to attract patients for medical tourism services[42] Other Information - The company has not reported any significant events after the reporting period[50] - The registered office and principal share transfer office in the Cayman Islands have been relocated as of April 1, 2020[49] - The company has not disclosed any interests or positions held by directors or senior management in any shares or related securities as of December 31, 2020[56] - The company has not granted any rights to directors or their associates to benefit from purchasing shares or debt securities of the company[63] - There were no arrangements made during the review period that would allow directors or key executives to benefit from purchasing shares or debt securities[63] - No new products or technologies have been mentioned in the provided documents[48] - No stock options were granted, exercised, canceled, or lapsed during the nine months ended December 31, 2020[64] - The company did not purchase, sell, or redeem any of its listed securities during the review period[65] - The company is assessing the operational situation of the Putian Edinburgh Friendly Hospital to develop future strategies[46]
金威医疗(08143) - 2021 Q3 - 季度财报